Temodar Shortage: What Providers and Prescribers Need to Know in 2026

Temozolomide (Temodar) is the backbone of standard-of-care treatment for newly diagnosed glioblastoma multiforme and anaplastic astrocytoma. For neuro-oncologists and oncology prescribers, supply disruptions to this medication present unique clinical, logistical, and ethical challenges. This guide provides a clinical overview of the 2026 supply landscape and practical frameworks for managing patients through it.

Supply Overview: Which Formulations Are at Risk?

The supply risk profile of temozolomide differs significantly by formulation:

Oral generic temozolomide: Relatively stable. Multiple manufacturers (Teva, Sun Pharma, Dr. Reddy's, Amneal) provide redundancy. Localized specialty pharmacy shortages can still occur but are typically resolvable by sourcing from an alternate manufacturer.

IV temozolomide (lyophilized powder for injection): More vulnerable. IV temozolomide has appeared on institutional oncology shortage lists. The IV formulation is used when patients cannot swallow capsules — a clinically significant gap in care if unavailable during active chemoradiation.

Brand Temodar (Merck): Not typically a supply concern because it is routed through specialty pharmacy and is not widely carried at retail. However, if a patient is specifically on brand for a clinical reason, ensure the specialty pharmacy is actively monitoring stock.

Clinical Considerations When Temozolomide Is Delayed

The stakes of a temozolomide delay depend heavily on the treatment phase:

Concurrent chemoradiation (Stupp protocol): This is the highest-risk phase for a delay. Temozolomide at 75 mg/m2 is given daily throughout radiotherapy. Any interruption in the concurrent phase may compromise the synergistic effect. Clinical judgment is required — ASHP recommends exhausting all supply alternatives before considering dose delays in this phase.

Maintenance phase (Cycles 1–6): A brief delay of a few days is generally less clinically significant than a delay in the concurrent phase. Document the reason and reschedule as quickly as possible.

Extended maintenance (beyond 6 cycles): If a patient is receiving adjuvant temozolomide beyond the standard 6 cycles (e.g., for anaplastic astrocytoma cycles 2–12), a brief delay is unlikely to materially affect outcomes, though this should be evaluated individually.

Managing IV-to-Oral Conversion During Shortage

FDA labeling and clinical pharmacokinetic data support equivalent exposure for IV and oral temozolomide at the same dose. If a patient is receiving IV temozolomide due to swallowing difficulty and IV supply is disrupted, consider:

Reassessing whether the patient can now tolerate oral capsules (condition may have changed)

Evaluating nasogastric or PEG tube administration of opened capsule contents (off-label but used clinically; consult pharmacy for guidance on handling hazardous drug powder)

Contacting your institution's pharmacy director about emergency allocation from hospital wholesalers

Substitution Considerations: When to Consider Alternatives

For MGMT-methylated newly diagnosed GBM, lomustine/temozolomide combination (CCNU/TMZ) is now supported by randomized trial data (CeTeG/NOA-09 study). If oral temozolomide is unavailable for an extended period, consulting on whether lomustine monotherapy or alternative regimens are appropriate is a time-sensitive decision that should involve the full neuro-oncology team.

For recurrent GBM, bevacizumab (Avastin) is FDA-approved and may be initiated at progression. PCV (procarbazine, lomustine, vincristine) is appropriate for 1p/19q co-deleted anaplastic oligodendroglioma. Always individualize the decision based on molecular profile, PS, and prior therapy.

38,717+ patients found their medications in stock

38K+

Find Temodar In Stock Today →

Communicating With Patients About Supply Issues

Transparency is critical. Patients on temozolomide are dealing with a serious cancer diagnosis and any uncertainty about their medication will compound distress. When communicating about supply issues:

Be proactive — don't wait until the day of the cycle to inform patients of a supply problem

Provide a clear action plan: what you are doing to resolve it, and what the patient should do

Contextualize the clinical impact — is a short delay expected to be clinically meaningful?

Direct patients to resources that can help them locate supply, such as medfinder

Tools for Providers: How medfinder Helps

medfinder for providers is a service that contacts pharmacies in a patient's area to identify which ones can fill a specific prescription. For oncology practices managing multiple patients on temozolomide, this can save enormous time and reduce the burden on your nursing and pharmacy staff. When a supply issue arises, direct patients to medfinder to help locate available supply near them.

See also: Temodar Shortage Update: What Patients Need to Know in 2026